Low-Intensity Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma: Effective Combination Treatment of Chronic-Phase Peyronie's Disease.
Müslüm Ergün, Süleyman Sağır
https://pubmed.ncbi.nlm.nih.gov/40191859Actively Recruiting
Phase Not Applicable
Age: 18Years - 65Years
MALE
Healthy Volunteers
ID07317297
Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease
Led by Uskudar University · Updated on 2026-01-16
50
Participants Needed
1
Research Sites
6 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of extracorporeal shock wave therapy in treating Peyronie's disease, a condition affecting the penis. This single-center, prospective clinical trial focuses on patients diagnosed with stable stage Peyronie's disease, meaning the condition has not worsened in pain or curvature for at least six months. The study is conducted by Uskudar University and aims to compare shock wave therapy with routine pharmacological treatment. Participants will be randomly assigned to one of two groups: one receiving standard pharmacological treatment without special intervention, and the other undergoing Extracorporeal Shockwave Therapy. The therapy involves eight treatment sessions, each delivering 3000 pulses at 2.5 bar pressure and 15 Hz frequency twice a week using a radial shockwave device. The shock waves target the penile plaque area through gel application on the penile shaft. Before and after treatment, participants will complete assessments including the International Erectile Function Index-5 and the Quality of Life Questionnaire short form to evaluate erectile function and quality of life. These outcomes will be measured at 5 weeks. The study monitors adherence and collects data to statistically analyze the therapy's impact on erectile function and quality of life over the study period.
CONDITIONS
Brief Title
Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease
Who Can Participate
Age: 18Years - 65Years
MALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Male individuals aged 18-65 years
- Diagnosed with stable Peyronie's Disease for at least 6 months
- Presence of palpable penile plaque
You will not qualify if you...
- Acute inflammatory stage of Peyronie's disease (painful, progressive)
- Previous surgery, needle therapy, or extracorporeal shockwave therapy for Peyronie's disease
- Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy
- History of penile cancer
- Severe erectile dysfunction
- Inability to comply with the study protocol or attend follow-up visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 4 weeks
Participants receive Extracorporeal Shockwave Therapy consisting of 8 sessions applied twice a week targeting the penile plaque.
8 treatment sessions twice a week
Follow-up
Duration - 1 week
Participants are evaluated after treatment using questionnaires to assess erectile function and quality of life.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Koreya Serq Tebabeti
Baku, Azerbaijan
Actively Recruiting
Loading map...
Research Team
Ö
Ömer ŞEVGİN
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients.
Hartmut Porst
https://pubmed.ncbi.nlm.nih.gov/32499189Non-surgical therapies for Peyronie's disease.
Joel E Rosenberg, Onuralp Ergun, Eu Chang Hwang...
https://pubmed.ncbi.nlm.nih.gov/37490423